Pharmaceuticals

Kintor Pharma Announces Brazil's ANVISA Approves Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients

SUZHOU, China, Sept. 26, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that onSeptember 22 the Brazilian Health Regulatory Agency (ANVISA) ...

2021-09-26 23:09 6358

Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit

Sept. 25, 2021, BOSTON /PRNewswire/ -- Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021. The annual World Bispecific Summit aiming to promote ...

2021-09-26 10:12 2356

New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA

HONG KONG, Sept. 24, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) ofChina has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and d...

2021-09-24 14:09 2269

Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206

SHANGHAI, Sept. 24, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, an...

2021-09-24 13:56 4450

Broncus Lists on Main Board of HKEx

HONG KONG, Sept. 24, 2021 /PRNewswire/ -- On September 24, Broncus (02216.HK), a pioneer in the field of interventional pulmonology inChina, was successfully listed on the main board of the Hong Kong Stock Exchange. Broncus, founded in 2012, is a medical device company focused on the development...

2021-09-24 11:52 6463

New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA

HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) ofChina has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and d...

2021-09-24 09:18 3931

Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases

- Pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine - NanoFlu™ vaccine candidate induced significantly enhanced cell-mediated immune responses - NanoFlu was well-tolerated with a comparable safety profile...

2021-09-24 08:47 5804

Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis

SAN FRANCISCO and SUZHOU, China, Sept. 24, 2021 /PRNewswire/ -- Innovent Biologics, Group. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major d...

2021-09-24 08:00 4047

Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine

* Novavax and Serum Institute of India file regulatory submission for World Health Organization Emergency Use Listing of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedic...

2021-09-23 21:59 7804

Nanoform Shortlisted For The European Small and Mid-Cap Awards 2021

HELSINKI, Sept. 23, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, has made the shortlist in the `Star of Innovation' category of the 9th annual European Small and Mid-Cap Awards. The nomination is based on Nanoform being a listed com...

2021-09-23 20:15 1696

BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO "Dr. Louis St. L. O'Dea" as CMO of BIORCHESTRA

BOSTON, Sept. 23, 2021 /PRNewswire/ -- BIORCHESTRA is a bio-tech company focused on the identification of novel targets in neurodegenerative diseases using RNA-based therapeutics. To access these novel targets, BIORCHESTRA has also developed a proprietary nanoparticle formulation to deliver RN...

2021-09-23 20:00 3047

Hainan Boao Lecheng International Medical Tourism Pilot Zone holds event to attract Japanese investment

The event is co-organized by Winhealth Pharma BOAO, China, Sept. 23, 2021 /PRNewswire/ -- The Hainan Boao Lecheng International Medical Tourism Pilot Zone ("Lecheng Pilot Zone")'s virtual promotional event to explain the favorable investment policies put in place for Japanese businesses, hosted ...

2021-09-23 16:15 3214

AstraZeneca and Oncoshot establish strategic partnership to better streamline recruitment process for cancer clinical trials

SINGAPORE, Sept. 23, 2021 /PRNewswire/ -- Singapore's cancer population may benefit from improved access to cutting-edge clinical trials through InSite Feasibility - Oncoshot's new digital platform that facilitates the efficient completion of oncology feasibility studies supported by near real-ti...

2021-09-23 16:07 4204

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Therapy for Esophageal Squamous Cell Carcinoma (ESCC)

SAN FRANCISCO and SUZHOU, China, Sept. 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2021-09-23 08:00 4288

MedAlliance announces completion of enrollment in Japanese SELUTION SLR™ Study

GENEVA, Sept. 23, 2021 /PRNewswire/ -- MedAlliance, with its Japanese partner MDK Medical, has completed enrollment in the clinical study of its novel Sirolimus Drug Eluting Balloon (DEB), SELUTION SLR™, for the treatment of peripheral arterial disease (PAD). This follows the acceptance of a Clin...

2021-09-23 08:00 3422

Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma

SUZHOU, China, and ROCKVILLE, MD, Sept 22, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel MDM2-p53 inhibitor alrizomadlin (A...

2021-09-23 07:40 2125

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

VANCOUVER, British Columbia and SHANGHAI, Sept. 23, 2021 /PRNewswire/ -- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a multi-year collaboration and lice...

2021-09-23 06:00 4594

INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico

News follows recent regulatory authorizations to proceed with the trial in Brazil and the Philippines INOVIO and partner Advaccine are collaborating on the global Phase 3 trial in regions underserved by COVID-19 vaccines; to focus onLatin America, Asia, and Africa PLYMOUTH MEETING, Pa., Sept. 2...

2021-09-22 20:00 5994

Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest

* Trial enrolled over 30,000 adult & elderly participants across 4 continents; 100% of SARS-CoV-2 strains observed in efficacy analysis were variants (Delta was predominant strain) * Primary and secondary efficacy endpoints were successfully met * 100% efficacy against severe COVID-19 & hosp...

2021-09-22 18:56 2591

Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug

SHELTON, Conn., Sept. 22, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the significant advantages gained by remdesivir encapsulation ...

2021-09-22 18:45 6117
1 ... 308309310311312313314 ... 339